New £1bn cancer research hub planned for South London
Plans have been unveiled for The London Cancer Hub, a state-of-the-art cancer research and laboratory hub to be located in…
Oncology
-
-
GSK’s Zejula reduces risk of progression and death in mesothelioma study
GSK’s Zejula (niraparib) has reduced the risk of death or progression by 27% in patients with mesothelioma in an investigator-led…
-
AstraZeneca’s Truqap fails in another Phase III trial
AstraZeneca has discontinued a Phase III trial of Truqap (capivasertib) after a review concluded that the study was unlikely to…
-
Boehringer’s HER2-mutated lung cancer drug shows sustained benefit for 14 months
Boehringer Ingelheim’s drug candidate for human epidermal growth factor receptor 2 (HER2)-mutated non-small cell lung cancer (NSCLC) has demonstrated a…
-
Kura doses first subjects in trial of ziftomenib for advanced GIST
Kura Oncology has dosed the first subjects in the open-label Phase Ia/Ib KOMET-015 trial, evaluating the oral investigational menin inhibitor…
-
New data from J&J’s bladder cancer drug-device trial strengthens support for NDA
Johnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in patients…
-
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials
ALX Oncology’s CD47-blocker evorpacept, in combination with MSD’s blockbuster Keytruda (pembrolizumab), has failed to show benefit in two Phase II…
-
Pfizer’s sasanlimab and BCG combo therapy improves EFS in bladder cancer trial
US-based pharmaceutical company Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for…
-
MSD reports outcomes from Keytruda combination trial for head and neck cancer
US-based pharmaceutical company MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating resected, locally advanced head…
-
CERo announces SCRI as main site for trial of CER-1236 to treat AML
CERo Therapeutics has announced that Colorado Blood Cancer Institute’s (CBCI) Sarah Cannon Research Institute (SCRI), US, will be the main site…
